Selected publications Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019 Academic Article GET IT Times cited: 9 Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discovery. 2017 Academic Article GET IT Times cited: 71
